Alzinova engages in discussions with potential partners and explores development strategies for ALZ-101 at BIO International Convention 2025 in Boston
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Alzinova AB (Nasdaq First North: ALZ) announces its participation in the BIO International Convention in Boston, USA, from June 16–19, 2025. As part of its ongoing efforts to strengthen its international presence, Alzinova will discuss development strategies for its vaccine candidate ALZ-101 and actively engage in ongoing discussions with potential collaboration partners ahead of the next clinical development phase.
“BIO 2025 is a key opportunity for Alzinova. We are going to Boston with a clear agenda: to continue our ongoing discussions with potential partners while paving the way for new collaborations that can support our Phase 2 initiative and future commercialization. Interest in innovative Alzheimer’s treatments is growing rapidly, and we are well positioned to take the next step,” says Tord Labuda, CEO of Alzinova.
ALZ-101 has recently completed a successful Phase 1b study, demonstrating a good safety profile and a robust immune response. The results also show promising effects on cognitive parameters and biomarkers, suggesting the potential to slow disease progression. The next step in the development program is a clinical Phase 2 study. Alzinova is currently evaluating various strategic options to advance the program, with a primary focus on finding a partner for its execution. At the same time, the company is also considering the possibility of funding and conducting the study independently.
The BIO International Convention is the world's largest and most comprehensive biotechnology event, with over 20,000 attendees. For Alzinova, it represents a vital opportunity to deepen relationships with leading pharmaceutical companies, investors, and experts in neurodegenerative diseases.
In advance of the event, Alzinova has already scheduled several meetings with potential partners and investors to discuss the next steps in the development of ALZ-101. The focus is on the planned Phase 2 study and evaluating strategic pathways forward, including how future development may enable commercialization. Through these discussions, Alzinova aims to strengthen its position as a relevant player in the fight against Alzheimer’s disease.
Business Development Director Sebastian Hansson will represent Alzinova at the event and will be available for individual meetings.
Summary Information about BIO International Convention
Date: June 16–19
Location: Boston Convention & Exhibition Center
More Information: https://convention.bio.org
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com